Women's Health & Pregnancy Clinical Trials

Statistical methods in women's health & pregnancy trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All women's health & pregnancy trials

790 results

• Reducing Pain of Lidocaine Injection: Complete Statistical AnalysisIndependent statistical analysis of Reducing Pain of Lidocaine Injection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02288364).Phase 4Results postedn = 88NCT02288364
• Reducing Preterm Births in Underserved Pregnant Women: Complete Statistical AnalysisIndependent statistical analysis of Reducing Preterm Births in Underserved Pregnant Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01344616).Phase 2Results postedn = 482NCT01344616
• RELAX-AHF-EUComplete statistical analysis of RELAX-AHF-EU, a randomized phase 3 trial evaluating serelaxin plus standard of care versus standard of care in patients with acute heart failure, including time-to-event, categorical, continuous, and longitudinal…Phase 3Results postedn = 2,666NCT02064868
• RELAX-AHF-EUIndependent statistical analysis of Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 2,666NCT02064868
• RENABLATE Feasibility Study CS156 (EC12-02) Study of Catheter Based Renal Denervation to Treat Resistant Hypertension: Complete Statistical AnalysisIndependent statistical analysis of RENABLATE Feasibility Study CS156 (EC12-02) Study of Catheter Based Renal Denervation to Treat Resistant Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 1Results postedn = 35NCT01756300
• Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography: Complete Statistical AnalysisIndependent statistical analysis of Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 4Results postedn = 656NCT00209417
• Renal Osteodystrophy: An Individual Management Approach: Complete Statistical AnalysisIndependent statistical analysis of Renal Osteodystrophy: An Individual Management Approach: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02440581).Phase NAResults postedn = 141NCT02440581
• Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors: Complete Statistical AnalysisIndependent statistical analysis of Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 4Results postedn = 11NCT03627299
• RESCUEIndependent statistical analysis of Renal Safety Evaluation After Dotarem®-Enhanced MRI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00650845).Phase 4Results postedn = 135NCT00650845
• RESPIREIndependent statistical analysis of Evaluating Smoking Cessation Protocols in Cancer Patients: NRT, MI, CBT or Hypnotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 21NCT04899492
• ROPIndependent statistical analysis of Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00634972).Phase 4Results postedn = 83NCT00634972
• SALTIndependent statistical analysis of Isotonic Solution Administration Logistical Testing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02345486).Phase NAResults postedn = 974NCT02345486
• SALT-EDIndependent statistical analysis and educational interpretation of SALT-ED, a randomized parallel-group trial comparing 0.9% saline with physiologically-balanced isotonic crystalloid in the emergency department.Phase NAn = 14,000NCT02614040
• SANDPIPERIndependent statistical analysis of A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase…Phase 3Results postedn = 631NCT02340221
• SAXAPCOSIndependent statistical analysis of Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 88NCT03480022
• SCD PED-02Independent statistical analysis of A Multi-Center Study of a SCD for Immunomodulatory Dysregulation in Pediatric AKI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 7NCT04869787
• SCORPIOComplete statistical analysis of the SCORPIO phase 3 trial of mirabegron in patients with symptoms of overactive bladder, including endpoint definitions, ANCOVA methodology, efficacy results, multiplicity, missing-data handling, and safety.Phase 3Results postedn = 2,336NCT00689104
• SIGNATUREIndependent statistical analysis of LDE225 for Patients With PTCH1 or SMO Mutated Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02002689).Phase 2Results postedn = 10NCT02002689
• sipITIndependent statistical analysis of Feasibility of Using sipIT Tools to Increase Compliance With Fluid Consumption Guidelines in Urolithiasis-Prone Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 31NCT03787615
• SISTErIndependent statistical analysis of Comparison of Surgical Procedures to Reduce Urinary Stress Incontinence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00064662).Phase 2/3Results postedn = 655NCT00064662
• Skylight 2Independent statistical analysis of A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2: primary endpoint results, effect estimate with confidence…Phase 3Results postedn = 501NCT04003142
• SOFTIndependent statistical analysis of Bladder Drainage During Labor: A Randomized Controlled Study of Obstetric Foley Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 139NCT00959920
• SOLO3Independent statistical analysis of Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received…Phase 3Results postedn = 266NCT02282020
• SOM230Independent statistical analysis of Pasireotide LAR in Severe Polycystic Liver Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01670110).Phase 2Results postedn = 48NCT01670110
• SONARIndependent statistical analysis of the phase 3 SONAR trial of atrasentan versus placebo in diabetic nephropathy, including the composite renal endpoint, hazard ratios, confidence intervals, p-values, trial design, and statistical methodology.Phase 3Results postedn = 5,107NCT01858532
• SPIRITIndependent statistical analysis of A Representational Intervention to Promote Preparation for End-of-life Decision Making: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01259011).Phase NAResults postedn = 210NCT01259011
• Split-DoseIndependent statistical analysis of Evaluation of Half-Dose Molecular Breast Imaging With Wide Beam Reconstruction Processing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 83NCT01653964
• STAGED-PKD-EXTIndependent statistical analysis of Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 24NCT04705051
• steroids/NECIndependent statistical analysis of Anti-inflammatory Treatment at the Onset of Necrotizing Enterocolitis (NEC) in Preterm Infants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 2NCT01156480
• TAPPASIndependent statistical analysis of Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 4Results postedn = 14NCT02806024
• TEMPO3:4Complete statistical analysis of the TEMPO3:4 phase 3 trial of tolvaptan versus placebo in autosomal dominant polycystic kidney disease, including trial design, endpoints, mixed-effects modeling, recurrent-event analysis, ANCOVA, and reported results.Phase 3Results postedn = 1,445NCT00428948
• TNBCIndependent statistical analysis of Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 50NCT02435680
• TRANQUILITYIndependent statistical analysis of A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 143NCT06362759
• TRANSFORMIndependent statistical analysis of Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 4Results postedn = 2,037NCT01950819
• VA NEPHRON-DComplete statistical analysis of VA NEPHRON-D, a randomized phase 3 trial evaluating combination ARB and ACEI therapy versus ARB monotherapy in patients with diabetic nephropathy, including time-to-event endpoints, hazard ratios, confidence intervals,…Phase 3Results postedn = 1,448NCT00555217
• VALUEIndependent statistical analysis of the VALUE phase 3 trial comparing valsartan and amlodipine in essential hypertension, including trial design, the registered composite cardiac endpoint, planned statistical analysis, and interpretation.Phase 3n = 15,313NCT06395194
• VELVETIndependent statistical analysis of A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor…Phase 2Results postedn = 213NCT01565083
• VIOLETIndependent statistical analysis of A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 438NCT03562156
• WI223281Independent statistical analysis of Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 17NCT03535506
• XEPADIndependent statistical analysis of An Observational Study of Xeloda (Capecitabine) in Participants With Metastatic or Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 274NCT01725386

← All therapeutic areas